Clinical trial
A Post-Marketing Clinical Pharmacokinetics Study of ART-123 in DIC Subjects With Renal Impairment
NCT01704001 is registered in ClinicalTrials.gov with Asahi Kasei Therapeutics Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Post-Marketing Clinical Pharmacokinetics Study of ART-123 in DIC Subjects With Renal Impairment
- Lead sponsor
- Asahi Kasei Therapeutics Corporation
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- October 31, 2012
- Completion date
- June 30, 2014
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.